Physician profile
Joe Smith
NPI 1760444608
$1,410.00
in general payments reported to CMS, 2019-2025
16 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $26.80 · 2021: $175 · 2022: $27.16 · 2023: $99.30 · 2024: $439 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $430.10 | 2019-2024 | Scopis Ent |
| Genzyme Corporation | $219.76 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $165.41 | 2021-2025 | Dupixent |
| Inspire Medical Systems, INC. | $134.73 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $122.18 | 2024 | |
| Glaxosmithkline, LLC. | $76.04 | 2024-2025 | Nucala |
| Intersect Ent, INC. | $38.81 | 2021 | |
| Medtronic, INC. | $38.42 | 2021-2023 | Propel |
| Acclarent, INC | $33.59 | 2019 | |
| Phathom Pharmaceuticals, INC. | $33.04 | 2024 | Voquezna |
| Optinose US, INC. | $31.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.37 | 2025 | |
| Amgen INC. | $18.63 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $16.26 | 2023 | |
| Arbor Pharmaceuticals, INC. | $13.94 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.